AC Immune SA (NASDAQ:ACIU) and InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

We can see in table 1 the earnings per share, top-line revenue and valuation of AC Immune SA and InVivo Therapeutics Holdings Corp.

Profitability

Table 2 provides us AC Immune SA and InVivo Therapeutics Holdings Corp.’s return on assets, return on equity and net margins.

Liquidity

The Current Ratio and a Quick Ratio of AC Immune SA are 5.1 and 5.1. Competitively, InVivo Therapeutics Holdings Corp. has 6.9 and 6.9 for Current and Quick Ratio. InVivo Therapeutics Holdings Corp.’s better ability to pay short and long-term obligations than AC Immune SA.

Institutional and Insider Ownership

The shares of both AC Immune SA and InVivo Therapeutics Holdings Corp. are owned by institutional investors at 27% and 12.4% respectively. Insiders held roughly 51.67% of AC Immune SA’s shares. Comparatively, InVivo Therapeutics Holdings Corp. has 0.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year AC Immune SA has stronger performance than InVivo Therapeutics Holdings Corp.

Summary

AC Immune SA beats on 6 of the 7 factors InVivo Therapeutics Holdings Corp.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s (AD), ParkinsonÂ’s, down syndrome, and glaucoma diseases. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.